Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:

Regulus Therapeutics Inc (NASDAQ:RGLS)’s shares picked up 13.97%, and closed at $21.13.

Regulus Therapeutics Inc. (RGLS): Kolchinsky co-founded RA Capital Administration in 2001 with Rich Aldrich, is pinning some of his hopes for great returns on in this quarter. First is Regulus Therapeutics Inc. (RGLS), the largest of his new positions. Kolchinsky opened a massive 4.74 million share position in the pre-clinical stage biopharmaceutical corporation, which accounted for 8.17% of his entire portfolio’s value, and placed it third among his long positions. That also amounted to a 9.8% passive position in the corporation, which Kolchinsky revealed in a filing in November.

That filing came shortly after Regulus absolutely spiked, more than tripling in value between October 17 and November 7. As with most early-stage biotech companies, the spike occurred because of positive results from one of the corporation’s trials, in this case based on results from its human proof-of-concept trial for the hepatitis C drug RG-101. Those trials showed not only a high cure rate in a short period of time from just a single subcutaneous treatment, but also showed positive results across varying genotypes of hepatitis C.

Microvision, Inc (NASDAQ:MVIS), raised 13.33%, and closed at $2.38.

Microvision Inc. (MVIS), a leader in innovative ultra-miniature projection display technology, declared it has signed a multi-year license contract with its Fortune Global 100 partner for MicroVision PicoP® display technology. The license contract marks an important milestone in the ongoing relationship between the two companies that began in April 2013.

The license contract grants the Fortune Global 100 corporation a non-exclusive license to MicroVision PicoP display technology for use in display modules it manufactures and sells. As part of the contract, MicroVision anticipates to receive an $8 million up-front license fee later this month. In addition to the initial up-front license fee, MicroVision will also receive royalties for display modules sold by the Fortune Global 100 corporation. Further terms of the license contract are confidential for competitive reasons.

The completion of the license contract is a very noteworthy step in this business relationship. The two companies began joint development on a display module incorporating PicoP display technology in April 2013. The development phase was accomplished in 2014, and the Fortune Global 100 corporation contracted with MicroVision for commercialization support services which are ongoing. The license contract represents a milestone achievement in MicroVision’s execution of its ingredient brand licensing business model. The Fortune Global 100 corporation will also purchase proprietary components from MicroVision for incorporation in its display modules following the license contract.

MicroVision is the creator of PicoP® display technology, an ultra-miniature laser projection solution for mobile consumer electronics, automotive head-up displays and other applications. MicroVision’s patented display technology assists OEMs break down display boundaries and offer improved visibility to mobile experiences.

bluebird bio Inc (NASDAQ:BLUE), enhanced 12.17%, and closed at $112.23, hitting new 52-week high of $112.53.

Formerly on February 25, bluebird bio, Inc. (BLUE), a clinical-stage corporation committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, stated business highlights and financial results for the fourth quarter and full year ended December 31, 2014.

Recent bluebird Highlights:

Presented data from beta-thalassemia program at the American Society of Hematology (ASH) annual meeting. In December 2014, bluebird bio presented data from its Northstar and HGB-205 studies demonstrating that the first four beta-thalassemia major patients treated with LentiGlobin® were transfusion free. The Northstar Study is an ongoing, open-label, single-dose, international, multi-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of subjects with beta-thalassemia major. The HGB-205 study is an ongoing, open-label, single-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin in the treatment of subjects with beta-thalassemia major and severe sickle cell disease. The data presented at ASH build upon data presented in June 2014 from the HGB-205 study at the European Hematology Association (EHA) annual meeting.

Advanced sickle cell disease program. In October 2014, as part of the HGB-205 study, bluebird bio became the first corporation to treat a sickle cell disease patient with gene therapy. The corporation also initiated the HGB-206 study, an open-label, multi-center, U.S.-based Phase 1 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of subjects with severe sickle cell disease.

Forthcoming Anticipated Milestones:

bluebird bio has outlined certain key aims for 2015, counting:

• Concluding enrollment for the Starbeam Study, in addition to the Northstar and HGB-205 studies. Ongoing enrollment for the HGB-206 study and presenting early clinical efficacy and safety data in patients with severe sickle cell disease at a major medical conference.
• Presenting additional data on beta-thalassemia major from the Northstar and HGB-205 studies at a major medical conference. Based on these additional data, the corporation looks forward to defining the regulatory path forward for LentiGlobin in beta-thalassemia major this year.

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs comprise Lenti-D™, presently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, presently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206).

Ur-Energy Inc. (USA) (NYSEMKT:URG), enhanced 12.02%, and closed at $ 1.05.

UR-Energy Inc. (URG), has filed the Corporation’s Annual Report on Form 10-K, Merged Financial Statements, and Administration’s Discussions & Analysis, all for the year ended December 31, 2014, with the U.S. Securities and Exchange Commission at www.sec.gov/edgar.shtml and with Canadian securities authorities on SEDAR at www.sedar.com. These filings also may be accessed on the Corporation’s website at www.ur-energy.com. Shareholders of the Corporation may receive a hard copy of the audited merged financial statements, free of charge, upon request to the Corporation.

Financial Results:

The Corporation ended the year with a cash and cash equivalents balance of $3.1 million. We recognized a gross profit of $11.5 million on sales of $29.3 million which represents a gross profit margin of about 39%. The Corporation realized an average price per pound sold of $51.22. Our cash cost per pound sold for the year was $19.73 while our total cost per pound sold was $34.49. The Corporation had an operating loss of $7.0 million after deducting total operating expenses of $18.5 million which comprises exploration and evaluation expenses, development expenses and general and administrative expenses. After recording interest and other expenses, the final net loss for the year was $8.7 million.

After concluding two sales in February 2015, our unrestricted cash position as of March 2, 2015 was $7.5 million. Given our current cash resources, contracted sales positions and low cash costs per pound, we do not anticipate raising additional funding in 2015 unless it becomes advantageous to do so.

Ur-Energy is a junior uranium mining corporation operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming. The Lost Creek processing facility has a two million pounds per year nameplate capacity. Ur-Energy engages in the identification, attainment, exploration development, and operation of uranium projects in the United States and Canada.